Skip to main content
logo
Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
29.43
0.00 (0.00%)
Aug 24, 2026, 9:32 AM EDT - Market open

Maze Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
20-167.5--
Revenue Growth
700.00%----
Gross Profit
20-167.5--
Selling, General & Admin
43.7634.4526.4224.6122.83
Research & Development
121.85108.4583.573.9588.19
Operating Expenses
165.61142.9109.9198.55111.03
Operating Income
-145.61-142.957.59-98.55-111.03
Interest & Investment Income
13.8211.784.651.972.03
Earnings From Equity Investments
-----3.54
EBT Excluding Unusual Items
-133.59-131.1262.24-96.59-112.54
Gain (Loss) on Sale of Investments
-----2.4
Other Unusual Items
---8.84-3.83-
Pretax Income
-133.59-131.1253.4-100.42-114.94
Income Tax Expense
--1.17--
Net Income
-133.59-131.1252.23-100.42-114.94
Preferred Dividends & Other Adjustments
--48.83--
Net Income to Common
-133.59-131.123.41-100.42-114.94
Net Income Growth
-----
Shares Outstanding (Basic)
5343222
Shares Outstanding (Diluted)
5343322
Shares Change
174.46%1474.04%19.33%13.82%-
EPS (Basic)
-2.52-3.051.42-43.89-57.18
EPS (Diluted)
-2.52-3.051.25-43.89-57.18
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-106.84-112.7374.81-87.27-101.17
Free Cash Flow Per Share
-2.01-2.6227.40-38.14-50.33
Gross Margin
100.00%-100.00%--
Operating Margin
-728.06%-34.38%--
Profit Margin
-667.95%-2.03%--
Free Cash Flow Margin
-534.20%-44.66%--
EBITDA
-143.71-140.560.88-94.46-107.21
EBITDA Margin
--36.35%--
D&A For EBITDA
1.912.43.34.093.82
EBIT
-145.61-142.957.59-98.55-111.03
EBIT Margin
--34.38%--
Effective Tax Rate
--2.20%--
SEC Filings: 10-K · 10-Q